Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis

• Published in: Clinical neurology and neurosurgery Vol. 213; p. 107134
• Main Authors: Zhang, Xuemei, Lian, Siheng, Zhang, Yingshi, Zhao, Qingchun
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2022; Elsevier Limited
• Subjects: Alzheimer's disease; Bias; Clinical trials; Cognitive ability; Dementia; Diarrhea; Donepezil; Efficacy; Intervention; Meta-analysis; Mild cognitive impairment; Nausea; Neurology; Patients; Safety; Side effects; Statistical analysis; Systematic review; Vomiting; Efficacy; Safety; Mild cognitive impairment; Donepezil; Meta-analysis
• ISSN: 0303-8467; 1872-6968
• DOI: 10.1016/j.clineuro.2022.107134

This study intends to systematically evaluate the efficacy and safety of donepezil for improving cognitive function in patients with mild cognitive impairment (MCI), and to provide evidence-based foundation for donepezil in MCI treatment. We searched in PubMed, Embase, Cochrane Library, Clinical trials.gov, Web of Science, CQVIP, and CNKI databases, and then we summarized the interventional and observational studies on the use of donepezil for improving the cognitive function of MCI patients. The literature was collected according to the inclusion criteria for data extraction. We evaluated the quality of the selected literature and used Stata 15.0 for meta-analysis. A total of 12 randomized controlled trials (RCTs) and 5 non-randomized concurrent controlled trials (CCTs) were included, and a total of 2847 patients were included. In terms of efficacy, meta-analysis showed that donepezil could significantly improve the MMSE (SMD: 0.85, 95%CI: 0.40–1.31) and MoCA (SMD: 1.88, 95%CI: 0.32–3.45) scores of MCI patients. Donepezil could not significantly reduce ADAS-cog score, nor could it significantly delay disease progression. The quality of the evidence was low overall. In terms of safety, donepezil could significantly increase the risk of adverse reactions such as nausea, vomiting, diarrhea in patients with MCI. Donepezil can improve the cognitive function of MCI patients to a certain extent. However, there is no trend of significantly delaying the progression of the disease, and it is easy to lead to the occurrence of adverse reactions. •This is a meta-analysis of donepezil for MCI.•Donepezil can improve the cognitive function in MCI patients.•Donepezil can't delay the progression of MCI to dementia.•Donepezil can significantly increase the risk of adverse reactions.